- Home
- BTAI vs EDSA Comparison
BTAI vs EDSA Comparison
Compare BTAI & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- EDSA
- Stock Information
- Founded
- BTAI 2017
- EDSA 2015
- Country
- BTAI United States
- EDSA Canada
- Employees
- BTAI N/A
- EDSA N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- EDSA Health Care
- Exchange
- BTAI Nasdaq
- EDSA Nasdaq
- Market Cap
- BTAI 7.2M
- EDSA 6.2M
- IPO Year
- BTAI 2018
- EDSA N/A
- Fundamental
- Price
- BTAI $1.88
- EDSA $2.35
- Analyst Decision
- BTAI Buy
- EDSA Strong Buy
- Analyst Count
- BTAI 5
- EDSA 1
- Target Price
- BTAI $42.60
- EDSA $21.00
- AVG Volume (30 Days)
- BTAI 1.2M
- EDSA 31.4K
- Earning Date
- BTAI 03-27-2025
- EDSA 05-09-2025
- Dividend Yield
- BTAI N/A
- EDSA N/A
- EPS Growth
- BTAI N/A
- EDSA N/A
- EPS
- BTAI N/A
- EDSA N/A
- Revenue
- BTAI $2,266,000.00
- EDSA N/A
- Revenue This Year
- BTAI $105.36
- EDSA N/A
- Revenue Next Year
- BTAI $46.93
- EDSA N/A
- P/E Ratio
- BTAI N/A
- EDSA N/A
- Revenue Growth
- BTAI 64.20
- EDSA N/A
- 52 Week Low
- BTAI $1.72
- EDSA $1.55
- 52 Week High
- BTAI $49.58
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- BTAI 39.27
- EDSA 50.89
- Support Level
- BTAI $1.76
- EDSA $2.37
- Resistance Level
- BTAI $2.37
- EDSA $2.55
- Average True Range (ATR)
- BTAI 0.28
- EDSA 0.11
- MACD
- BTAI 0.03
- EDSA -0.01
- Stochastic Oscillator
- BTAI 16.95
- EDSA 25.93
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.